Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health ...

Zydus Lifesciences' ZyVac TCV receives WHO prequalification, eligible for U.N. procurement, combating typhoid fever in ...

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV.

Zydus Lifesciences Ltd has received approval from the WHO for its Typhoid conjugate vaccine, ZyVac TCV, to be procured by United Nations agencies. Developed in Ahmedabad, it targets ages 6 months to ...

Zydus Lifesciences's Typhoid Vi conjugate vaccine, ZyVac TCV, has received WHO prequalification, making it eligible for UN ...

Bollywood publicist Rohini Iyer hosted a glamorous Diwali party at a popular Mumbai eatery, drawing in a constellation of stars from the film industry. The guest list was a veritable who's who of ...

As per GAVI (2022) it is estimated that Typhoid accounts for an estimated 11 to 21 million cases of febrile illness and ...

ZyVac TCV is designed for active immunization against Salmonella typhi infection in individuals aged 6 months to 65 years.

Zydus Lifesciences advanced 1.71% to Rs 1,005.05 after the company received in principle acceptability from World Health Organisation (WHO) for its ZyVac TCV vaccine.

Indian multinational pharmaceutical company Zydus Lifesciences Ltd on Wednesday announced that its Typhoid Vi conjugate ...

Zydus Lifesciences' shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, ...

Prime Minister Narendra Modi and Chinese President Xi Jinping held their first meeting in five years during the Brics Summit in Russia's Kazan.